摘要
目的:评估在曲普瑞林联合重组人生长激素(rhGH)对特发性矮小症(ISS)患儿身高获益、骨龄(BA)、激素水平及安全性的影响。方法:纳入2022年6月—2024年6月中国人民解放军联勤保障部队第九〇四医院就诊的ISS患儿96例,随机分为观察组(采用人生长激素注射液+曲普瑞林治疗,n=48)与对照组(采用人生长激素注射液治疗,n=48),两组均治疗12个月。比较两组身高标准差分值差值(ΔHt-SDS)、年生长速率标准差(GV-SDS)、BA/实际年龄(CA)、BA与CA差值[Δ(BA-CA)]、促性腺激素释放激素(GnRH)激发试验的黄体生成素(LH)峰、静息LH与卵泡刺激素(FSH),LH峰<3 IU/L及雌二醇(E_(2))/睾酮(T)处于儿童参考范围占比,并监测两组不良事件发生情况。结果:观察组ΔHt-SDS与治疗12个月后GV-SDS高于对照组,Δ(BA-CA)低于对照组(P<0.05);两组治疗12个月后BA/CA比较差异无统计学意义(P>0.05)。治疗12个月后,观察组GnRH激发试验的LH峰、静息LH与FSH低于对照组,LH峰<3 IU/L与E_(2)/T处于儿童参考范围占比高于对照组(P<0.05)。两组不良事件发生率比较差异无统计学意义(P>0.05)。结论:rhGH联合曲普瑞林可于治疗12个月后进一步提高ISS患儿的身高获益、减缓骨龄进展并更有效抑制性腺轴。
Objective:To evaluate the effect of Triptorelin combined with recombinant human growth hormone(rhGH)on height gain,bone age(BA),hormone levels,and safety in children with idiopathic short stature(ISS).Method:A total of 96 children with ISS who were treated at the 904 Hospital of the Chinese People's Liberation Army Joint Logistics Support Force from June 2022 to June 2024 were randomly divided into the observation group(treated with Recombinant Human Growth Hormone Injection+Triptorelin,n=48)and the control group(treated with Recombinant Human Growth Hormone Injection,n=48).Both groups were treated for 12 months.The difference in height standard deviation scores(ΔHt-SDS),annual growth rate standard deviation(GV-SDS),BA/chronological age(CA),the difference between BA and CA[Δ(BA-CA)],the luteinizing hormone(LH)peak in the gonadotropin-releasing hormone(GnRH)stimulation test,resting LH and follicle-stimulating hormone(FSH),the proportions of LH peaks<3 IU/L and estradiol(E_(2))/testosterone(T)within the reference range of children were compared between the two groups.The occurrence of adverse events in the two groups was monitored.Result:TheΔHt-SDS and GV-SDS after 12 months of treatment in the observation group were higher than those in the control group,andΔ(BA-CA)was lower than that in the control group(P<0.05).There was no statistically significant difference in BA/CA between the two groups after 12 months of treatment(P>0.05).After 12 months of treatment,the LH peak in the GnRH stimulation test,resting LH and FSH of the observation group were lower than those of the control group,and the proportions of LH peak<3 IU/L and E_(2)/T within the reference range of children were higher than those of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion:The rhGH combined with Triporelin can further increase the height gain of children with ISS after 12 months of treatment,slow down the progression of bone age and more effectively inhibit the gonadal axis.
作者
金鑫玲
王静
李晓云
JIN Xinling;WANG Jing;LI Xiaoyun(Pediatric Department of the 904 Hospital of the Chinese People's Liberation Army Joint Logistics Support Force,Wuxi 214044,China;不详)
出处
《中国医学创新》
2025年第35期49-53,共5页
Medical Innovation of China
关键词
曲普瑞林
重组人生长激素
特发性矮小症
Triptorelin
Recombinant human growth hormone
Idiopathic short stature
